CHICAGO, June 18, 2021 /PRNewswire/ -- According to the new market research report "Electroceuticals/Bioelectric Medicine Market by Product (Pacemaker, ICD, Cochlear Implant, Deep Brain, Spinal Cord, Vagus, Sacral Nerve Stimulators), Application (Ischemia, Epilepsy), Type (Implantable, Noninvasive), End User - Global Forecast to 2026", published by MarketsandMarkets™, the global Electroceuticals Medicine Market is projected to reach USD 21.5 billion by 2026 from USD 16.8 billion in 2021, at a CAGR of 5.0%.
Browse in-depth TOC on "Electroceuticals/Bioelectric Medicine Market" 250 – Tables 43 – Figures 264 – Pages
The rising geriatric population and subsequent growth in the prevalence of neurological & cardiovascular disorders drives growth in the Bioelectric Medicine Market, rising government support & funding for neurological disorders, and the increasing investments and funding for research on CRM devices are among the other factors. Emerging economies such as China and Japan are providing lucrative opportunities for the players operating in the electroceuticals market.
The cardiac pacemakers & implantable cardioverter defibrillators segment accounted for the largest share of the electroceuticals market, by product segment, in 2020
Based on product, the Electroceuticals Medicine Market is segmented into cardiac pacemakers & implantable cardioverter defibrillators, spinal cord stimulators, cochlear implants, deep brain stimulators, transcutaneous electrical nerve stimulators, vagus nerve stimulators, sacral nerve stimulators & gastric electrical stimulators, and other electrical stimulators. The cardiac pacemakers & implantable cardioverter defibrillators segment accounted for the largest share of the electroceuticals market in 2020. Factors such as the increasing incidence of arrhythmias and rising technological advancements are boosting the market growth of this segment.
Noninvasive electroceutical devices segment to register the highest growth rate during the forecast period
The Electroceuticals Medicine Market is segmented into implantable electroceutical devices and noninvasive electroceutical devices. In 2020, the noninvasive electroceutical devices segment accounted for the highest growth rate. Factors such as the rising R&D investments by companies for novel product development and technological advancements are contributing to the growth of this segment.
The hospitals, clinics, and ASCs segment accounted for the largest share of the electroceuticals market, by end user segment, in 2020
Based on end users, the Electroceuticals Medicine Market has been segmented into hospitals, clinics, and ASCs; and other end users. In 2020, the hospitals, clinics, and ASCs segment accounted for the largest share of the electroceuticals market. The improving healthcare infrastructure in developing countries is driving this segments growth.
North America is the largest regional market for Bioelectric Medicine Market
The global Electroceuticals Medicine Market is segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the electroceuticals market. The large share of this region can be attributed to the increasing healthcare spending and the highly developed healthcare system in the US and Canada.
The major players operating in this Bioelectric Medicine Market are Medtronic plc (Ireland), Boston Scientific Corporation (US), Abbott Laboratories, Inc. (US), LivaNova PLC (UK), Cochlear Ltd. (Australia), MicroPort Scientific Corporation (China), Sonova Group (Switzerland), Nevro Corp. (US), Axonics Modulation Technologies, Inc. (US), Neuronetics, Inc. (US), Second Sight Medical Products, Inc. (US), NeuroPace, Inc. (US), BIOTRONIK (Germany), Medico S.p.A. (Italy), Nurotron Biotechnology Co. Ltd. (US), MED-EL (Austria), Aleva Neurotherapeutics SA (Switzerland), NeuroSigma, Inc. (US), BioWave Corporation (US), Soterix Medical Inc. (US), Bioinduction Ltd. (UK), GiMer Medical (Taiwan), Cefaly (Belgium), BioControl Medical (Israel), and tVNS Technologies GmbH (Germany).
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.